Any of you medical types understand what the ramifications of giving the still-experimental Regeneron monoclonal antibody cocktail to Trump at the same time he is undergoing a regimen of Remdesavir might be?
It seems like that could be risky, given the experimental nature of one (if not both) of the treatments. But maybe they are so unrelated in their functions that they would not likely have any interaction with one another?
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links